. "Appendix D Meeting Agenda." Assessment of the Role of Intermittent Preventive Treatment for Malaria in Infants: Letter Report. Washington, DC: The National Academies Press, 2008.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Assessment of the Role of Intermittent Preventive Treatment for Malaria in Infants: Letter Report
Appendix D Meeting Agenda
Meeting of the Committee on the Perspectives on the Role of Intermittent PreventiveTreatment of Malaria in Infants
January 9, 2008–January 11, 2008
American Public Health Association (APHA)
800 I (Eye) Street, N.W.
Washington, DC 20001-3710
Main Floor, Conference Room A
Wednesday, January 9, 2008—APHA Conference Room A
OPEN SESSION
10:15am–10:45am
Welcoming Remarks
Patrick Kelley, M.D., Dr.P.H.
Director, Board on Global Health, IOM
Myron M. Levine, M.D., D.T.P.H.
Director, Center for Vaccine Development, University of Maryland School of Medicine, and IOM Committee Chair
10:45am–11:15am
Remarks from Sponsor (phone conference)
David Brandling-Bennett, M.D., D.T.P.H.
Project Officer, Bill & Melinda Gates Foundation
11:15am–11:45am
Antimalarial Drugs and Drug Resistance
Christopher Plowe, M.D., M.P.H.
Professor of Medicine, Epidemiology and Preventive Medicine, and Microbiology and Immunology; Chief, Center for Vaccine Development’s Malaria Section, University of Maryland, and IOM Committee Member
11:45am–12:15pm
Malaria Overview and Burden of Malaria in Infancy
Miriam Laufer, M.D., M.P.H.
Assistant Professor of Pediatrics, Division of Infectious Diseases and Tropical Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, and IOM Committee Member
12:15pm–12:45pm
Childhood Immunizations/EPI in Developing Country Context
Neal Halsey, M.D.
Professor, Department of International Health, Johns Hopkins Bloomberg School of Public Health, and IOM
Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole. Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 76
Assessment of the Role of Intermittent Preventive Treatment for Malaria in Infants: Letter Report
Appendix D
Meeting Agenda
Meeting of the Committee on the Perspectives on the Role of Intermittent Preventive Treatment of Malaria in Infants
January 9, 2008–January 11, 2008
American Public Health Association (APHA)
800 I (Eye) Street, N.W.
Washington, DC 20001-3710
Main Floor, Conference Room A
Wednesday, January 9, 2008—APHA Conference Room A
OPEN SESSION
10:15am–10:45am
Welcoming Remarks
Patrick Kelley, M.D., Dr.P.H.
Director, Board on Global Health, IOM
Myron M. Levine, M.D., D.T.P.H.
Director, Center for Vaccine Development, University of Maryland School of Medicine, and IOM Committee Chair
10:45am–11:15am
Remarks from Sponsor (phone conference)
David Brandling-Bennett, M.D., D.T.P.H.
Project Officer, Bill & Melinda Gates Foundation
11:15am–11:45am
Antimalarial Drugs and Drug Resistance
Christopher Plowe, M.D., M.P.H.
Professor of Medicine, Epidemiology and Preventive Medicine, and Microbiology and Immunology; Chief, Center for Vaccine Development’s Malaria Section, University of Maryland, and IOM Committee Member
11:45am–12:15pm
Malaria Overview and Burden of Malaria in Infancy
Miriam Laufer, M.D., M.P.H.
Assistant Professor of Pediatrics, Division of Infectious Diseases and Tropical Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, and IOM Committee Member
12:15pm–12:45pm
Childhood Immunizations/EPI in Developing Country Context
Neal Halsey, M.D.
Professor, Department of International Health, Johns Hopkins Bloomberg School of Public Health, and IOM
OCR for page 77
Assessment of the Role of Intermittent Preventive Treatment for Malaria in Infants: Letter Report
Committee Member
12:45pm–1:30pm
Lunch
1:30pm–1:45pm
Overview of the IPTi Consortium
Pedro Alonso, M.D., Ph.D.
Director, Barcelona Centre for International Health Research at the Hospital Clinic and Professor at the University of Barcelona
1:45pm–2:15pm
Pooled Efficacy of Intermittent Preventive Treatment for Malaria in Infants with Sulfadoxine-Pyrimethamine (IPTi-SP)
John Aponte, M.D., M.Sc.
Research Professor and Head, Statistics Unit of the Barcelona Centre for International Health Research (CRESIB)
2:15pm–2:30pm
Break
2:30pm–4:30pm
Acceptability, Cost-Effectiveness, Drug Resistance, Applicability of IPTi-SP, Effectiveness Study of IPTi-SP (five presentations)
David Schellenberg, M.B.B.S., D.T.M.H., M.R.C.P., Ph.D.
Professor, Malaria and International Health, London School of Hygiene and Tropical Medicine
4:30pm–5:10pm
United Nations Children’s Fund (UNICEF) Pilot Implementation of IPTi-SP
Alexandra de Sousa, M.D., Ph.D.
Operational Research Coordinator, Unit of Policy and Evidence, UNICEF
5:10pm–5:30pm
IPTi Consortium Policy Process
Andrea Egan, Ph.D.
Coordinator, IPTi Consortium
5:30pm–5:40pm
Concluding Remarks, Questions, Public Announcement of Change to Next Day’s Schedule with WHO Speaker Starting at 8:15am.
Myron M. Levine, M.D., D.T.P.H.
IOM Committee Chair
Thursday, January 10, 2008—APHA Conference Room A
OPEN SESSION
8:15am–9:00am
World Health Organization’s Global Malaria Program: Considerations of IPTi-SP Within Context of Malaria Control Program
Dr. Peter Olumese, M.B., FMCPaed
Case Management and Research Team, Global
OCR for page 78
Assessment of the Role of Intermittent Preventive Treatment for Malaria in Infants: Letter Report
Malaria Programme, World Health Organization
9:00am–10:10am
Pooled Safety of IPTi-SP
Sir Alasdair Breckenridge, M.D., M.Sc.
Chairman, UK Medicines and Healthcare Products Regulatory Agency
10:10am–10:20am
Break
10:20am–10:50am
Potential Impact of IPT on Spread of Drug-Resistant Malaria: Considerations from Mathematical Modeling
Wendy Prudhomme O’Meara, Ph.D.
Research Associate NIH/Fogarty Center, Centre for Geographic Medicine Research, KEMRI-Wellcome Trust Research Center, Kenya
10:50am–11:30am
Program Implementation Challenges in a Developing Country Context
Carol Medlin, Ph.D., M.P.A.
Professor, Anthropology and Social Medicine, University of California, San Francisco
11:30am–12:00pm
Kisumu—Results from First Trial of IPTi with Alternative Drugs to Sulfadoxine-Pyrimethamine
Larry Slutsker, M.D., M.P.H.
Chief, Malaria Branch of the U.S. Centers for Disease Control and Prevention
12:15pm–1:15pm
Lunch for Speakers and Registered Guests in Conference Room A
CLOSED LUNCH SESSION FOR COMMITTEE, Conference Room C
1:15pm–2:15pm
Open Question-and-Answer Session
2:15pm–2:55pm
Considerations for the Implementation of IPTi (by phone)
Brian Greenwood, M.D.
Manson Professor of Clinical Tropical Medicine, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine
2:55pm–3:52pm
Public Comment and Question Session
3:52pm
Concluding Remarks and Adjournment to Closed Sessions
Myron M. Levine, M.D., D.T.P.H.
IOM Committee Chair
Patrick Kelley, M.D., Dr.P.H.
Director, IOM Board on Global Health
